Mia Glerup1, T Herlin2, M Twilt2,3. 1. Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Blvd 99, 8200, Aarhus, Denmark. miagleru@rm.dk. 2. Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark. 3. Department of Pediatrics, Division of Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
Abstract
PURPOSE OF REVIEW: This review assesses the long-term remission and predictors of clinical outcome in patients with juvenile idiopathic arthritis (JIA). A comprehensive literature search was performed including articles published between January 1, 2004 and February 28, 2017. Studies, with a minimum follow-up of 24 months, were selected independently by two reviewers based on in- and exclusion criteria. The objective outcome was inactive disease/clinical remission as defined by the Wallace criteria at last follow-up. RECENT FINDINGS: The probability of achieving inactive disease and/or clinical remission is dependent on the JIA subcategories studied in the different articles. Overall, a significant proportion of JIA patients still showed signs of active disease at last follow-up. Some studies include patient populations followed for 15 years or more and these patients were exposed to different treatment protocols at disease presentation than patients diagnosed in the biologic era. Although the severity of the morbidity and associated mortality risk has decreased over time, a significant proportion of the current JIA patients still do not reach an inactive disease status within a 2-year follow-up window. Studying the long-term outcome of patients with JIA remains challenging due to the heterogeneity of the study designs and study populations. Although improvement has been shown in the biologic era, we still need to enhance the number of patients with inactive disease within the first 2 years after diagnosis.
PURPOSE OF REVIEW: This review assesses the long-term remission and predictors of clinical outcome in patients with juvenile idiopathic arthritis (JIA). A comprehensive literature search was performed including articles published between January 1, 2004 and February 28, 2017. Studies, with a minimum follow-up of 24 months, were selected independently by two reviewers based on in- and exclusion criteria. The objective outcome was inactive disease/clinical remission as defined by the Wallace criteria at last follow-up. RECENT FINDINGS: The probability of achieving inactive disease and/or clinical remission is dependent on the JIA subcategories studied in the different articles. Overall, a significant proportion of JIA patients still showed signs of active disease at last follow-up. Some studies include patient populations followed for 15 years or more and these patients were exposed to different treatment protocols at disease presentation than patients diagnosed in the biologic era. Although the severity of the morbidity and associated mortality risk has decreased over time, a significant proportion of the current JIA patients still do not reach an inactive disease status within a 2-year follow-up window. Studying the long-term outcome of patients with JIA remains challenging due to the heterogeneity of the study designs and study populations. Although improvement has been shown in the biologic era, we still need to enhance the number of patients with inactive disease within the first 2 years after diagnosis.
Authors: H M Albers; D M C Brinkman; S S M Kamphuis; L W A van Suijlekom-Smit; M A J van Rossum; E P A H Hoppenreijs; H J Girschick; C Wouters; R K Saurenmann; J J Houwing-Duistermaat; T W J Huizinga; M W Schilham; R ten Cate Journal: Arthritis Care Res (Hoboken) Date: 2010-02 Impact factor: 4.794
Authors: Jaime Guzman; Kiem Oen; Adam M Huber; Karen Watanabe Duffy; Gilles Boire; Natalie Shiff; Roberta A Berard; Deborah M Levy; Elizabeth Stringer; Rosie Scuccimarri; Kimberly Morishita; Nicole Johnson; David A Cabral; Alan M Rosenberg; Maggie Larché; Paul Dancey; Ross E Petty; Ronald M Laxer; Earl Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Kristin Houghton; Lynn Spiegel; Stuart E Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth; Suzanne E Ramsey; Alessandra Bruns; Johannes Roth; Sarah Campillo; Susanne Benseler; Gaëlle Chédeville; Rayfel Schneider; Shirley M L Tse; Roxana Bolaria; Katherine Gross; Brian Feldman; Debbie Feldman; Bonnie Cameron; Roman Jurencak; Jean Dorval; Claire LeBlanc; Claire St Cyr; Michele Gibbon; Rae S M Yeung; Ciarán M Duffy; Lori B Tucker Journal: Ann Rheum Dis Date: 2015-05-18 Impact factor: 19.103
Authors: J de Oliveira Sato; T Albuquerque Pedrosa Fernandes; C Bicalho do Nascimento; J E Corrente; C Saad-Magalhaes Journal: Clin Exp Rheumatol Date: 2013-11-14 Impact factor: 4.473
Authors: Carol A Wallace; Sarah Ringold; John Bohnsack; Steven J Spalding; Hermine I Brunner; Diana Milojevic; Laura E Schanberg; Gloria C Higgins; Kathleen M O'Neil; Beth S Gottlieb; Joyce Hsu; Marilynn G Punaro; Yukiko Kimura; Audrey Hendrickson Journal: J Rheumatol Date: 2014-09-01 Impact factor: 4.666
Authors: Maria Ekelund; Kristiina Aalto; Anders Fasth; Troels Herlin; Susan Nielsen; Ellen Nordal; Suvi Peltoniemi; Marite Rygg; Marek Zak; Lillemor Berntson Journal: Pediatr Rheumatol Online J Date: 2017-02-22 Impact factor: 3.054
Authors: Flora McErlane; Chris Anderson; Saskia Lawson-Tovey; Barbara Lee; Chris Lee; Laura Lunt; Janet E McDonagh; Andrew D Smith; Nicola Smith; Gavin Cleary Journal: Pediatr Rheumatol Online J Date: 2022-06-18 Impact factor: 3.413
Authors: Annie Yarwood; Stephanie Shoop-Worrall; Elena López-Isac; Samantha Louise Smith; Andrew P Morris; John David Bowes; Melissa Tordoff; Kimme L Hyrich; Wendy Thomson; Stephen Eyre Journal: Rheumatology (Oxford) Date: 2022-10-06 Impact factor: 7.046
Authors: Patricia Vega-Fernandez; Tracy V Ting; Edward J Oberle; Courtney McCracken; Janet Figueroa; Mekibib Altaye; Amy Cassedy; Gurjit S Kaeley; Johannes Roth Journal: Arthritis Care Res (Hoboken) Date: 2021-07-30 Impact factor: 5.178